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Background: Neopterin (NPT) is a catabolic product of guanosine triphosphate, is synthesized by macrophages and, and when elevated in plasma, 
is indicative of a pro-inflammatory immune status. NPT has been shown to be markedly elevated in patients with heart failure (HF). This study 
examined the long-term effects of electrical baroreflex stimulation (Barostim) with the Rheos® System (CVRx® Inc., Minneapolis, MN) on plasma NPT 
in dogs with coronary microembolization-induced HF (LV ejection fraction, EF, between 22% and 30%).
Methods: Dogs with HF (n=14) were randomized to 6 months monotherapy with Barostim n=7) or no therapy at all (control, n=7). Plasma NPT 
levels were evaluated in all HF dogs at baseline, prior to induction of HF, after induction of HF at time of randomization (pre-treatment, PRE) and 
again after 6 months of follow-up (post-treatment, POST).
Results: Results are depicted in the table. In all dogs, EF decreased significantly after the induction of HF. In control HF dogs, EF decreased further 
between PRE and POST whereas in Barostim-treated HF dogs EF increased between PRE and POST. Plasma NPT increased markedly in all dogs after 
induction of HF. In control dogs, NPT remained elevated at POST but was normalized at POST in Barostim-treated dogs.
Conclusions: Chronic Barostim therapy in dogs with advanced HF improves LV function and normalizes plasma levels of NPT. In addition to its 
other potential benefits, Barostim therapy can be viewed as anti-inflammatory in the setting of chronic HF.
EF and Plasma NPT in Dogs With HF
Control (n=7) Barostim Therapy (n=7)
Baseline PRE POST Baseline PRE POST
EF (%) 53±1 27±1* 22±1† 54±2 24±1* 29±1†
Plasma NPT (ng/ml) 1.18±0.07 2.67±0.34* 3.00±0.34† 1.19±0.06 4.13±0.98* 1.54±0.28†
*=p<0.05 Base vs. PRE; †=p<0.05 PRE vs. POST
